Why are you looking at An2 Therapeutics?
Capability
Service linesRESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Work mix: 100% prime · 0% sub · primary NAICS 541715 / PSC AN12 HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Where they win
Sole agencyRecompete exposure: None
No incumbent recompetes detected in the next 24 months.
Agency buyer map
1 buyersRecompete exposure
NoneNo incumbent recompetes detected in the next 24 months.
No incumbent recompetes detected in the next 24 months.
GET THE FULL BRIEF
Get An2 Therapeutics’s recompete exposure, top agencies and teaming history
The outlook above is free to read and verify — an estimated $4.9M in play. Enter a work email for two figures the page cannot show.
“After 35 years in federal contracting, I've seen what separates the firms that win from the ones that wonder why they lost. What SCOUT does is put the kind of competitive and market intelligence in front of BD teams…”
Enter your company name and we'll build the page.
Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →
Frequently asked questions
What federal contracts does An2 Therapeutics hold?
An2 Therapeutics (UEI DD4FE2GE4L78) shows $4.9M across 1 award actions in SCOUT’s public USASpending-backed profile, with Department of Health and Human Services (HHS) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.
Which agencies does An2 Therapeutics work with?
An2 Therapeutics’s firm-wide obligated mix is led by Department of Health and Human Services (HHS) (100%).
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →